Gufic Biosciences Limited has informed the Exchange about Copy of Newspaper Publication
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gufic Biosciences Limited published its audited financial results for Q4 and FY 2025-26 in newspapers on May 30, 2026, as required under SEBI regulations. For FY26, total standalone income dropped significantly to Rs 135,431.61 lakhs from Rs 201,948.54 lakhs in FY25. Net profit after tax fell to Rs 3,443.54 lakhs from Rs 5,362.99 lakhs in the previous year, representing roughly a 36% decline. EPS reduced to Rs 23.02 from Rs 35.85 year-on-year. Consolidated results similarly showed lower profitability compared to the prior year. The results were reviewed by the Audit Committee and approved by the Board on May 29, 2026.
The significant decline in both revenue and profitability for FY26 may concern shareholders. The company appears to have faced headwinds during the year, with net profit more than halving. Investors should monitor for management commentary on the reasons for this performance deterioration.